SU2C creates interdisciplinary Dream Teams that connect top-tier scientists, clinicians, patient advocates, and other experts across institutions to expedite the discovery process for new cancer treatments.
What we learn about one cancer often has great application to others. That’s why research and clinical trials are vital to getting effective treatments to patients. More than 180 clinical trials have been funded by SU2C, and over $603 million has been pledged to the work of more than 1,500 scientists.
“The best dollar spent on cancer research in this country.”
When new areas of research are identified that could have significant patient impact and potential for breakthrough, SU2C acts quickly to push proposals in these areas from concept to reality. SU2C’s research teams study many cancer types, with a focus on today’s most innovative areas of cancer therapy, such as immunotherapy and epigenetics.
Progress against one cancer is progress against all cancers. See what SU2C scientists are working on now.
SU2C’s network of scientists are laser-focused on research developments that can be moved quickly from the lab to the clinic. This approach, called translational research, brings new treatments to patients who need them now by closely involving clinical trial teams.
Learn how SU2C research models leverage collaboration, strategic risk-taking, and translational research to produce better results, faster.
The annual SU2C Summit unites SU2C-funded researchers from multiple areas of study to allow the SU2C model of collaboration to realize its full potential. Top scientists share findings, ideas, and progress reports, thereby fostering greater discovery, increasing transparency, promoting additional collaboration across teams and research programs, and encouraging thinking outside the traditional research silos.
“We bring in diverse expertise, anyone who can help with the cancer problem, including mathematicians, astrophysicists, computer scientists and the like. And that adds an incredible dimension.”
